Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy

NCT07711314 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
48
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborators